The Japanese Journal of Gastroenterological Surgery
Online ISSN : 1348-9372
Print ISSN : 0386-9768
ISSN-L : 0386-9768
Autologous Blood Transfusion for Esophageal Cancer Treated with Chemoradiotherapy Followed by Esophagectomy
Matsuo NagataTakehide AsanoHiroshi YamamotoNobuhiro TakiguchiOsamu KainumaHiroaki SohdaMikito MoriKentaro MurakamiKazuo WatanabeChikara Sakai
Author information
JOURNAL FREE ACCESS

2005 Volume 38 Issue 8 Pages 1271-1279

Details
Abstract

Purpose: Autologous blood transfusion has been shown to be useful as a means of avoiding the problems associated with allogeneic transfusion, such as transmission of bacteria and viruses, and immunological reactions, such as allergy, graft-versus-host disease, and suppression of tumor immunity. This study retrospectively investigated the usefulness of autologous blood donation in esophageal cancer treated by chemoradiotherapy (CRT) followed by surgery. Patients and Methods: Between June 2000 and October 2003, 59 patientswith resectable esophageal cancer were treated by preoperative CRT, consisting of 5FU 700-800mg/m2 days1-5, Nedaplatin 80mg/m2 (or Cisplatin 70mg/m2) day 1, and 30Gy of radiation days 1-19. The criteria for autologous blood donation were: Hb value greater than 11g/dl, body weight greater than 40kg, and having obtained informed consent in writing. Autologous blood was collected 1 and 2 weeks before surgery, anderythropoietin was injected on the day of each blood donation. Esophagectomy was performed by right thoracotomy and laparotomy, and a cervical or intrathoracic anastomosis was created between the esophagus andgastric tube by the stapling technique. The autologous blood donor (ABD) group was compared with a nonautologous blood donor (NABD) group who were treated by the same preoperative CRT schedule and satisfied the criteria for autologous blood donation between Aug 1998 and May 2000. Results: The Hb value of 49 (83.1%) of the 59 patients treated by preoperative CRT was higher than 11g/dl, and 400-800ml (mean 662.2±158.5ml) of autologous blood was successfully collected from the 45 patients (76.3%) who weighed morethan 40kg. Allogeneic blood transfusion during the perioperative period was avoided in only 1 patient (9.1%) in the NABD group. In the ABD group, on the other hand, allogeneic blood products, including MAP, FFP and PPF, were avoided in 36 patients (83.7%). There were no significant differences between the twogroups in postoperative complications or Hb, serum total protein, and albumin values. Conclusion: These results indicate that autologous blood donation is useful as a means of avoiding allogeneic blood transfusion inesophageal cancer patients treated by preoperative CRT and surgery.

Content from these authors

この記事はクリエイティブ・コモンズ [表示 - 非営利 4.0 国際]ライセンスの下に提供されています。
https://creativecommons.org/licenses/by-nc/4.0/deed.ja
Next article
feedback
Top